These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22083905)

  • 1. Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
    Oh KW; Kim DY; Lee YS; Kang MI;
    J Bone Miner Metab; 2012 May; 30(3):359-66. PubMed ID: 22083905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women.
    Flood EM; Beusterien KM; Green H; Shikiar R; Baran RW; Amonkar MM; Cella D
    Health Qual Life Outcomes; 2006 Jul; 4():42. PubMed ID: 16834773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
    Vlak T; Kaštelan D; Lozo P; Aljinović J; Gradišer M; Mijić S; Nikolić T; Miškić B; Car D; Tajšić G; Dušek T; Jajić Z; Grubišić F; Poljičanin T; Bakula M; Džubur F; Strižak-Ujević M; Kadojić M; Radman M; Vugrinec M; Kuster Z; Pekez M; Radović E; Labar L; Crnčević-Orlić Z; Koršić M
    Clin Rheumatol; 2011 Dec; 30(12):1549-54. PubMed ID: 21956235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver J; van den Bergh JP; Nguyen AM; Sajjan S;
    Osteoporos Int; 2016 Mar; 27(3):1227-1238. PubMed ID: 26637321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
    Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
    J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
    Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
    Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    García-Hernández P; Carranza-Lira S; Motta-Martínez E
    Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
    Lai PS; Chua SS; Chan SP
    Int J Clin Pharm; 2013 Aug; 35(4):629-37. PubMed ID: 23677816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.
    Modi A; Ebeling PR; Lee MS; Min YK; Mithal A; Yang X; Baidya S; Sen S; Sajjan S
    Arch Osteoporos; 2017 Dec; 12(1):65. PubMed ID: 28718004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
    Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.